Harry Destecroix co-founded Ziylo while studying for his PhD at the University of Bristol. Ziylo, a university spin-out company, developed a synthetic molecule allowing glucose to bind with the bloodstream more effectively. Four years later, and by then a Phd, Destecroix sold the company to Danish firm Novo Nordisk, one of the biggest manufacturers of […]...